Millions of people who are unable to take statins, the
first-choice treatment for high cholesterol, due to side effects may now have a
new option. In a recent study, researchers found that taking bempedoic acid, a
drug known as Nexletol, can reduce the risk of heart attacks and other
cardiovascular issues in individuals who cannot tolerate statins. Doctors had
previously prescribed bempedoic acid, in combination with a statin, to help
certain high-risk patients lower their cholesterol, but this is the first
evidence that the drug can be used independently for this purpose.
A recent five-year study, published in the New England
Journal of Medicine and presented Saturday at a meeting of the American College
of Cardiology, has found that daily intake of the cholesterol-lowering drug
Nexletol can reduce the risk of major cardiac problems by 13%, heart attacks by
23%, and procedures to unclog arteries by 19%. The study, involving 14000
people, further revealed the efficacy of bempedoic acid is comparable to statins
in reducing deaths.
Dr. Steven Nissen of the Cleveland Clinic, who led the
study, stated, "though statins remain the cornerstone of
cholesterol-lowering therapies, people with statin intolerance can be highly
benefitted by this introduction." He added, "Sometimes statins cause
serious muscle pain in some people making the individuals who are otherwise
eligible for medication unable to or unwilling to take it. Nexletol blocks
cholesterol production in the liver but differently than statins without causing
the muscle side effect."
The research, funded by the drug's maker Esperion Therapeutics, suggests
that use of bempedoic acid as a cholesterol-lowering drug could be an effective
alternative to statins for patients who are unable or unwilling to take them. However,
Dr. John H. Alexander of Duke University warns that while the results are
compelling, they should not be used as a replacement for statins, which are
still the best choice for most patients.
Comprising seasoned professionals and experts from the medical field, the IJCP editorial team is dedicated to delivering timely and accurate content and thriving to provide attention-grabbing information for the readers. What sets them apart are their diverse expertise, spanning academia, research, and clinical practice, and their dedication to upholding the highest standards of quality and integrity. With a wealth of experience and a commitment to excellence, the IJCP editorial team strives to provide valuable perspectives, the latest trends, and in-depth analyses across various medical domains, all in a way that keeps you interested and engaged.
Please login to comment on this article